In summary, our study demonstrates that EZH2 overexpression is significantly associated with high grade triple-negative breast carcinoma as well as corresponding DCIS, plus many high-grade HER2-positive breast carcinomas. The gene discussed is EZH2; the disease is ductal breast carcinoma in situ.